Mycobacterium mucogenicum bacteremia in immune-compromised patients, 2008-2013. Diagn Microbiol Infect Dis 2016 Jun;85(2):182-5
Date
04/28/2016Pubmed ID
27117516DOI
10.1016/j.diagmicrobio.2016.02.012Scopus ID
2-s2.0-84964211718 (requires institutional sign-in at Scopus site) 7 CitationsAbstract
Mycobacterium mucogenicum (MM) is a rapidly growing nontuberculous mycobacterium that may rarely cause bacteremia in immune-compromised hosts. All MM cases from 2008 to 2013 were analyzed across 4 risk groups: stem cell transplantation (SCT), hematologic malignancy, solid tumors, and others. Descriptive analysis was performed, as well as comparative analysis of neutropenic patients (absolute neutrophil count ≤1000/μL) with nonneutropenic patients. Of 39 MM cases, 27 patients had undergone SCT. Neutropenia was present in 12 patients. There was a significant difference in the presence of fever at the time of MM bacteremia between neutropenic and nonneutropenic groups (92% versus 42%; P=0.005). Central venous catheter (CVC) was present in 33 cases. All patients were treated with >1 antibiotic. Most frequently used combination antibiotic regimen involved clarithromycin and amikacin. Median duration of antibiotic treatment was 42days. Bacteremia resolved in all cases with CVC removal and combination antibiotic treatment.
Author List
Abidi MZ, Ledeboer N, Banerjee A, Hari PAuthors
Anjishnu Banerjee PhD Associate Professor in the Institute for Health and Equity department at Medical College of WisconsinParameswaran Hari MD Adjunct Professor in the Medicine department at Medical College of Wisconsin
Nathan A. Ledeboer PhD Vice Chair, Professor in the Pathology department at Medical College of Wisconsin
MESH terms used to index this publication - Major topics in bold
AdultAged
Aged, 80 and over
Anti-Bacterial Agents
Bacteremia
Humans
Immunocompromised Host
Male
Middle Aged
Mycobacterium Infections, Nontuberculous
Retrospective Studies
Risk Factors
Treatment Outcome
Young Adult
